Tokyo, Japan, Mar 4, 2008 - (JCN Newswire) - Eisai Co., Ltd. (TSE: 4523) announced today that Vasolan(R) Tablets 40mg (generic name: verapamil hydrochloride) received approval for the additional indications of the treatment of atrial fibrillation/flutter and paroxysmal supraventricular tachycardia. This approval makes Vasolan the first oral form of calcium channel blockers approved for the treatment of tachyarrhythmia in Japan.
